As of 2026-09-24, the EV/EBITDA ratio of Vanda Pharmaceuticals Inc (VNDA) is -1.91. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. VNDA's latest enterprise value is 256.52 mil USD. VNDA's TTM EBITDA according to its financial statements is -134.07 mil USD. Dividing these 2 quantities gives us the above VNDA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.7x - 16.4x | 15.5x |
| Forward P/E multiples | 16.5x - 19.1x | 18.3x |
| Fair Price | (35.92) - (35.74) | (36.90) |
| Upside | -812.7% - -809.2% | -832.2% |
| Date | EV/EBITDA |
| 2026-09-23 | -1.91 |
| 2026-09-22 | -1.99 |
| 2026-09-21 | -1.96 |
| 2026-09-18 | -1.95 |
| 2026-09-17 | -1.94 |
| 2026-09-16 | -1.90 |
| 2026-09-15 | -1.89 |
| 2026-09-14 | -1.96 |
| 2026-09-11 | -1.94 |
| 2026-09-10 | -1.91 |
| 2026-09-09 | -2.01 |
| 2026-09-08 | -2.04 |
| 2026-09-04 | -2.09 |
| 2026-09-03 | -2.05 |
| 2026-09-02 | -2.13 |
| 2026-09-01 | -2.08 |
| 2026-08-31 | -2.07 |
| 2026-08-28 | -2.03 |
| 2026-08-27 | -2.09 |
| 2026-08-26 | -2.05 |
| 2026-08-25 | -2.09 |
| 2026-08-24 | -2.04 |
| 2026-08-21 | -2.02 |
| 2026-08-20 | -2.07 |
| 2026-08-19 | -2.15 |
| 2026-08-18 | -2.09 |
| 2026-08-17 | -2.01 |
| 2026-08-14 | -1.99 |
| 2026-08-13 | -1.91 |
| 2026-08-12 | -1.98 |
| 2026-08-11 | -1.86 |
| 2026-08-10 | -1.90 |
| 2026-08-07 | -1.90 |
| 2026-08-06 | -1.95 |
| 2026-08-05 | -1.94 |
| 2026-08-04 | -2.04 |
| 2026-08-03 | -2.00 |
| 2026-07-31 | -1.94 |
| 2026-07-30 | -1.98 |
| 2026-07-29 | -1.92 |
| 2026-07-28 | -1.97 |
| 2026-07-27 | -1.99 |
| 2026-07-24 | -1.98 |
| 2026-07-23 | -2.06 |
| 2026-07-22 | -2.05 |
| 2026-07-21 | -2.11 |
| 2026-07-20 | -2.04 |
| 2026-07-17 | -2.09 |
| 2026-07-16 | -2.10 |
| 2026-07-15 | -2.28 |